Text Size: a  |   a 

Pipeline Drug: Thymosin Beta 4

February 4, 2016

RegeneRx Biopharmaceuticals, Inc., announced the publication of a research article detailing the process by which Thymosin beta 4 (tb4), the company’s novel therapeutic peptide, effectively promoted the remyelination process in two separate animal models commonly used for multiple sclerosis (MS) research. The article was published in the journal Neurobiology of Disease.

Researchers from the Departments of Neurology and Biostatistics and Research Epidemiology, Henry Ford Health System in Detroit, and from the Department of Physics at Oakland University in Rochester, both in Michigan, showed that TB4 is an effective remyelination therapy, able to promote proliferation and differentiation of OPCs into mature, myelin-producing oligodendrocytes, while also decreasing axonal damage.

Two different animal models extensively used in MS research, the experimental autoimmune encephalomyelitis (EAE) model and the cuprizone diet model, were used to evaluate this potential mechanism of CNS repair. In both, the improved rate of remyelination and mature oligodendrocytes generation significantly correlated with functional improvement in the mice.
Findings indicated that:

  • TB4 increases proliferation of OPCs and the maturation of OPCs to myelinating oligodendrocytes which in concert, likely contribute to the beneficial effect of the drug.
  • Epidermal Growth Factor Receptor upregulated and activated by TB4 may mediate the process of OPC differentiation
  • TB4 could potentially be developed as a therapy for MS patients, and for other demyelinating neurological disorders